The Chemours
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 4 months.
- Its last 5 Sell calls were actually followed by a +7% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -7.4% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 9.7% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation A+
How expensive the stock is versus earnings, sales and its own 5-year history.
| Forward P/E | 10.7x | Better than 76% |
| Price / Sales | 0.3x | Better than 95% |
Growth F
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | -5.3% | Better than 12% |
| Net income CAGR (3Y) | -51.6% | Better than 3% |
| Free cash flow CAGR (3Y) | -51.5% | Better than 4% |
Profitability D
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 15.5% | Better than 12% |
| Operating margin | -0.5% | Better than 21% |
| Net margin | -6.6% | Better than 18% |
| Return on equity | -90.4% | Better than 6% |
| Return on invested capital | -3.9% | Better than 23% |
Momentum C-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -21.9% | Better than 28% |
| 6-month return | -41.3% | Better than 11% |
| 12-month return (ex latest month) | 17.6% | Better than 56% |
| Distance below 52-week high | 61.4% | Better than 10% |
Financial Health D
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.8x | Better than 50% |
| Debt to assets | 59.5% | Better than 9% |
| Interest coverage | 0.0x | Better than 24% |
| Free cash flow / net income | 77.3% | Better than 25% |
Analyst View C+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 33.3% | Better than 15% |
| Upside to average target | 55.2% | Better than 70% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 11.80
- Open
- 11.67
- Day range
- 10.83 - 11.92
- Avg price
- 11.09
- Volume
- 3.14M
- Turnover
- 34.79M
- Turnover ratei
- 2.10%
- Volume ratioi
- 1.36
- Amplitudei
- 9.20%
- 52-week rangei
- 10.77 - 28.22
Valuation
- P/Ei
- -4.23
- P/E (TTM)i
- -10.67
- P/Bi
- 10.56
- EPSi
- -2.57
- Book value / shi
- 1.03
- Net profit
- -386.87M
- Net assets
- 155.05M
Share structure
- Market cap
- 1.64B
- Float capi
- 1.63B
- Shares out
- 150.53M
- Float sharesi
- 149.60M
Dividend & listing
- Div yield (TTM)i
- 3.22%
- Dividend (TTM)
- 0.35
- Listing date
- 1970-01-01
61.4% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-8.42M net over the window
Short interest
- Shares short
- 14.54M
- % of floati
- 9.66%
- Days to coveri
- 6.85
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of The Chemours (CC)?
The Chemours last traded at 10.88. This page shows a periodic quote snapshot. Check the displayed quote time.
What is The Chemours's market cap?
About 1.64B.
What is the P/E ratio of The Chemours?
The trailing twelve-month P/E is -10.67, below its own 5-year average of 4.09 — toward the bottom of its historical range (14.43% percentile). See the Valuation tab for the full history.
Does The Chemours pay a dividend?
Yes. The trailing dividend yield is 3.22%. Per-share dividends have risen or held for 7 straight years through 2025. See the Dividends tab for the full payment history.
Is The Chemours a buy according to analysts?
The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 16.89, which implies 55.2% upside from the current price. This is not investment advice.
What is The Chemours's StockVane Quant Rating?
The StockVane Momentum strategy currently rates The Chemours a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:47:46 · For reference only, not investment advice and not tailored to your situation.
The Chemours discussion 0 comments